BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20418245)

  • 1. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.
    Montes-Moreno S; Gonzalez-Medina AR; Rodriguez-Pinilla SM; Maestre L; Sanchez-Verde L; Roncador G; Mollejo M; García JF; Menarguez J; Montalbán C; Ruiz-Marcellan MC; Conde E; Piris MA
    Haematologica; 2010 Aug; 95(8):1342-9. PubMed ID: 20418245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.
    Wilkinson ST; Vanpatten KA; Fernandez DR; Brunhoeber P; Garsha KE; Glinsmann-Gibson BJ; Grogan TM; Teruya-Feldstein J; Rimsza LM
    Blood; 2012 Feb; 119(6):1459-67. PubMed ID: 22167754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
    Morley AM; Verity DH; Meligonis G; Rose GE
    Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 5. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.
    Colomo L; Loong F; Rives S; Pittaluga S; Martínez A; López-Guillermo A; Ojanguren J; Romagosa V; Jaffe ES; Campo E
    Am J Surg Pathol; 2004 Jun; 28(6):736-47. PubMed ID: 15166665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.
    Hu M; Trevino J; Yang L; Cao D; Liu X; Lai J
    In Vivo; 2018; 32(2):413-417. PubMed ID: 29475930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.
    Montes-Moreno S; Montalbán C; Piris MA
    Leuk Lymphoma; 2012 Feb; 53(2):185-94. PubMed ID: 21812534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.
    Liu YY; Leboeuf C; Shi JY; Li JM; Wang L; Shen Y; Garcia JF; Shen ZX; Chen Z; Janin A; Chen SJ; Zhao WL
    Blood; 2007 Jul; 110(1):339-44. PubMed ID: 17379744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmablastic Lymphoma: A Review of Clinicopathologic Features and Differential Diagnosis.
    Harmon CM; Smith LB
    Arch Pathol Lab Med; 2016 Oct; 140(10):1074-8. PubMed ID: 27684979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
    Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
    Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
    Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse large B-cell lymphomas with plasmablastic differentiation.
    Teruya-Feldstein J
    Curr Oncol Rep; 2005 Sep; 7(5):357-63. PubMed ID: 16091196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.
    Li J; Zhao S; Wang J; Chen J; Wen W; Zhang Q
    Tumour Biol; 2016 Mar; 37(3):3619-37. PubMed ID: 26459310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
    Chu PG; Loera S; Huang Q; Weiss LM
    Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diffuse large B-cell lymphoma with expression of anaplastic lymphoma kinase protein: clinicopathologic and immunohistochemical study of 5 cases].
    Wang WY; Ma ZG; Li GD; Liu WP; Zhong L; Wang Y; Li JM; Li L; Jiang W; Tang Y; Liao DY
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):529-34. PubMed ID: 17134546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
    Wang L; Wang W; Li X; Guo Y; Zhu X
    Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
    Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
    Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
    Pasqualucci L; Compagno M; Houldsworth J; Monti S; Grunn A; Nandula SV; Aster JC; Murty VV; Shipp MA; Dalla-Favera R
    J Exp Med; 2006 Feb; 203(2):311-7. PubMed ID: 16492805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.
    Valera A; Colomo L; Martínez A; de Jong D; Balagué O; Matheu G; Martínez M; Taddesse-Heath L; Jaffe ES; Bacchi CE; Campo E
    Mod Pathol; 2013 Oct; 26(10):1329-37. PubMed ID: 23599149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.
    Garcia JF; Roncador G; García JF; Sánz AI; Maestre L; Lucas E; Montes-Moreno S; Fernandez Victoria R; Martinez-Torrecuadrara JL; Marafioti T; Mason DY; Piris MA
    Haematologica; 2006 Apr; 91(4):467-74. PubMed ID: 16585013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.